Skip Navigation
Leading research to understand, treat, and prevent infectious, immunologic, and allergic diseases
Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

2010 NIAID Technology Transfer and Partnerships

NIAID is committed to making sure that NIAID-supported discoveries move steadily from the laboratory toward development into products such as approved vaccines, treatments, or diagnostic tools that improve public health. The project development trajectory can be long. The NIAID Office of Technology Development (OTD) pursues collaborations with industry, academia, non-profit organizations, and other government agencies to ease exchange of research information and materials and to facilitate the translation of research findings, technologies, and materials into useful products.

Collaborative ventures are supported by various agreements, including cooperative research and development agreements (CRADAs) and research collaboration agreements (RCAs). These partnerships leverage NIAID resources to develop

  • Effective HIV/AIDS prevention strategies, vaccines, and treatments
  • Medical countermeasures to protect against emerging and re-emerging infectious diseases and for use in biodefense
  • Interventions for immune-mediated diseases, including asthma and allergic diseases

FY 2010 NIAID Technology Development Activities

  • NIAID negotiated 11 new CRADAs to develop products like these:
    • Novel diagnostic tests for monitoring and detection of infections and immune disorders
    • Models of tissue fibrosis, or scarring, following infection
    • Novel vaccine or treatment strategies against viral infections including seasonal influenza, Chikungunya virus, pneumovirus, and HIV
    • Methods to prevent the lethal effects of anthrax toxins
  • NIAID established 48 new RCAs.
  • NIAID collaborated with the National Institutes of Health Office of Technology Transfer to attract investment partners for further research and development of technologies through appropri­ate license and collaboration agreements. These agreements included the following technologies:
    • Compounds that treat and prevent the spread of malaria
    • Modified cell-culture systems to study the interactions between hepatitis C virus and HIV co-infections
    • A new vaccine against Strongyoides stercoralis, a parasitic infection that affects an estimated 100 to 200 million people worldwide
    • Small molecules to improve vaccine responses against multiple flavivirus infections, such as dengue fever, West Nile virus, and St. Louis encephalitis
  • NIAID established a Technology Transfer Fellowship Program that trains talented researchers interested in understanding the Institute’s rapidly evolving technology transfer needs.
Fiscal Year Total Number of U.S. Patents in Force at End of FY License Agreements in Effect Total Active CRADAs
NIAID Technology Transfer Activities–Activities resulting from NIAID intramural research.
Data show patents, licenses, and CRADAs in force on September 30 of the fiscal year indicated.

Learn more about technology development at NIAID:

Last Updated November 17, 2011

Last Reviewed August 03, 2011